Bristol-Myers Squibb Company
SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS

Last updated:

Abstract:

The present invention relates to polypeptides which include tenth fibronectin type III domains (.sup.10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding .sup.10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

Status:
Application
Type:

Utility

Filling date:

16 Nov 2021

Issue date:

30 Jun 2022